Blog

  • Roland TD-27KV2 & Alesis Strata Prime Electronic Drums: Making The Right Choice

    Roland TD-27KV2 & Alesis Strata Prime Electronic Drums: Making The Right Choice

    Key Takeaways

    • Roland’s TD-27KV2 features digital pads with multi-sensor snare technology and Prismatic Sound Modeling that captures acoustic drum nuances
    • Alesis Strata Prime delivers 40GB of factory BFD samples through a 10.1-inch touchscreen interface with 360-degree cymbals for natural acoustic feel
    • Roland excels in MIDI implementation and studio recording with superior dynamic response, while Alesis offers larger playing surfaces and modern connectivity
    • Price comparison reveals significant value differences, with build quality and resale considerations affecting long-term investment returns
    • Jazz and session players typically prefer Roland’s authentic response, while rock and electronic musicians gravitate toward Alesis’ extensive sound library

    Electronic drumming has reached a crossroads where technology meets artistry. Today’s premium kits deliver experiences that blur the line between digital and acoustic, but choosing between flagship models requires understanding their fundamental differences. These two powerhouse kits represent distinct philosophies in electronic percussion, each targeting specific player needs and musical applications.

    Digital Pads vs Touchscreen Technology

    Roland’s TD-27KV2 transforms electronic drumming through digital pad technology that changes how drums respond to playing. The PD-140DS snare contains multiple individual sensors that track strike position, velocity, and technique with surgical precision. This 14-inch pad sends digital data directly to the module, eliminating the analog-to-digital conversion that creates latency in traditional triggers.

    The 18-inch CY-18DR digital ride cymbal extends this innovation to cymbal work. Five dedicated sensors differentiate between bow, bell, and edge strikes while tracking the exact impact location. Touch a zone with your finger to mute it, just like an acoustic cymbal. The VH-14D digital hi-hat completes the digital trio with dual-sensor technology that captures every foot movement and stick articulation.

    Alesis takes a different approach with the Strata Prime’s 10.1-inch touchscreen module. Navigate through sounds, effects, and settings like using a tablet computer. The interface eliminates the frustrating button-pressing of traditional LCD modules. Sam Ash’s detailed comparison highlights how this touchscreen technology makes complex sound editing accessible to players who previously avoided deep module programming.

    The Strata Prime compensates for standard analog triggers with massive processing power. While the pads use traditional mesh and rubber construction, the module’s multi-core processor instantly accesses over 215,000 individual samples from the renowned BFD sound engine. This computational approach creates realism through sheer sample variety rather than sensor sophistication.

    Sound Engine Showdown

    Roland’s Prismatic Sound Modeling Technology

    Prismatic Sound Modeling represents Roland’s breakthrough in electronic drum synthesis. Rather than playing back static samples, the TD-27 module calculates drum behavior in real time. Strike the snare center and the system models shell resonance, drumhead tension, and harmonic content. Move to the rim and entirely different physics calculations create the appropriate sound.

    This technology extends beyond simple velocity switching. The module tracks multiple strike parameters simultaneously: where you hit, how hard, the angle of attack, and even the type of stick. A brush stroke on the snare produces the characteristic swish and texture of actual brush technique, not a recorded sample of someone else playing brushes.

    PureAcoustic Ambience Technology adds virtual room acoustics to headphone monitoring. The system places virtual microphones around a modeled drum kit in various acoustic spaces. Close-mic the snare for punchy attack or pull back for natural room reflection. These aren’t reverb effects but actual acoustic modeling of how drums sound in different environments.

    Alesis BFD Engine with 40GB Sound Library

    The Strata Prime runs FXpansion’s legendary BFD drum engine with over 40 gigabytes of meticulously recorded factory samples. Every kit piece includes multiple velocity layers, round-robin variations, and positional samples. The 20-inch kick drum alone contains hundreds of individual recordings captured from different microphone positions and playing techniques.

    BFD’s approach prioritizes authentic acoustic recordings over mathematical modeling. Professional drummers recorded every sample in world-class studios using vintage and modern drum kits. The engine randomly selects from multiple recordings of each velocity level, preventing the machine-gun effect that plagues lesser electronic kits.

    The 75 factory kits span decades of recorded music history. Play classic rock with a 1970s Ludwig kit, dive into modern metal with processed samples, or work with world percussion through ethnic drum collections. Each kit loads instantly despite the massive file sizes, thanks to intelligent sample streaming and memory management.

    Playing Experience That Matters

    Response Time and Feel Differences

    Roland’s digital pads achieve extremely low latency from stick strike to sound output. This near-instantaneous response eliminates the disconnect that plagues many electronic kits. Fast rolls, ghost notes, and complex sticking patterns translate perfectly without timing lag. The digital connection bypasses traditional trigger-to-audio conversion entirely.

    The Alesis Strata Prime operates with slightly higher latency, still excellent for most playing situations but noticeable during ultra-fast technical passages. The slight delay becomes more apparent when switching between electronic and acoustic drums during the same session. However, the larger playing surfaces often compensate by improving accuracy and reducing missed hits.

    Dynamic range separates professional from amateur electronic kits. Roland’s digital pads capture 127 discrete velocity levels with consistent response across the entire range. Whisper-quiet ghost notes register distinctly from moderate strokes, while thunderous power hits maintain clarity without digital clipping. This dynamic precision makes Roland the studio standard for electronic drums.

    Pad Sizes and Playability

    Size matters in electronic drumming, and Alesis provides generous playing surfaces throughout the Strata Prime kit. The 20-inch kick drum dwarfs Roland’s compact 10-inch KD-10 trigger. Double bass drummers appreciate the larger target area and more realistic foot positioning. The full-sized kick also creates impressive visual presence on stage.

    Tom sizes follow suit with 8-inch, 10-inch, 12-inch, and 14-inch mesh heads compared to Roland’s three 10-inch PDX-100 pads. Larger toms accommodate players accustomed to acoustic kit proportions and reduce accuracy demands during energetic performances. The size difference becomes important for drummers with less precise stick control.

    Roland’s digital pads sacrifice some size for technological advancement. The 14-inch digital snare matches most acoustic snares, while the 18-inch digital ride provides adequate playing area for most techniques. The smaller tom sizes force slight adjustment from acoustic players but deliver unmatched response accuracy once adapted.

    MIDI Implementation for Recording

    MIDI implementation reveals each kit’s studio recording capabilities. Roland’s TD-27KV2 transmits incredibly detailed MIDI data with individual note assignments for every articulation. Hi-hat position sends as continuous controller data, enabling realistic closed-to-open transitions in drum software. The multi-channel MIDI output accommodates complex multi-track recording scenarios.

    Every major drum software package includes Roland preset mappings. Load Superior Drummer or BFD and start recording immediately without complex MIDI mapping. The detailed velocity curves and note assignments translate perfectly to software instruments, making the TD-27KV2 an exceptional MIDI controller even when using external sounds.

    Alesis provides solid MIDI implementation with good software compatibility, though without Roland’s microscopic detail level. The standard trigger outputs work reliably with most drum software, requiring occasional mapping adjustments for perfect integration. The touchscreen interface makes MIDI assignments more intuitive than traditional menu-driven systems.

    Build Quality and Hardware Design

    Roland MDS Rack System Construction

    Roland constructs the TD-27KV2 around their legendary MDS rack system, engineered for professional touring durability. Heavy-gauge steel tubes connect through precision-machined metal clamps that lock securely and resist loosening from constant setup and breakdown. Memory locks on every joint maintain consistent positioning across multiple venues.

    The module housing exemplifies Roland’s overbuilt philosophy. Thick ABS plastic with metal reinforcement plates protects the electronics while metal-collared cable connections prevent wear from repeated plugging and unplugging. This kit survives load-ins, tear-downs, and everything between without compromising performance.

    Compact engineering maximizes functionality within a 5-foot by 6-foot footprint. The digital pads mount in fixed positions optimized for their sensor arrays, limiting creative positioning but ensuring optimal response. Most players find the standard configuration works excellently for both practice and performance applications.

    Alesis Steel Frame Components

    The Strata Prime uses a four-post steel rack with secure locking clamps throughout. While not quite matching Roland’s overbuilt standard, the construction provides excellent stability for the larger pad configuration. The steel tubing handles normal use reliably, though extended touring might reveal durability differences compared to Roland’s tank-like construction.

    Alesis maximizes visual impact through generous proportions and professional aesthetics. The 360-degree ARC cymbals mount on traditional acoustic cymbal arms, allowing natural movement and positioning flexibility. This freedom improves playing feel but requires more setup space and careful positioning for optimal response.

    The touchscreen module represents modern industrial design with clean lines and premium materials. Build quality appears solid for studio and moderate live use, though probably better suited for permanent installations than heavy road work. The large screen creates impressive visual presence but requires careful handling during transport.

    Price and Value Analysis

    Current Pricing at Sam Ash

    The Alesis Strata Prime commands $3,999, positioning it firmly in professional territory alongside flagship models from major manufacturers. This price reflects the touchscreen technology, massive sample library, and larger pad configuration. The premium pricing targets serious drummers willing to pay for advanced features and extensive sound variety.

    Roland’s TD-27KV2 typically retails around $3,499, but Sam Ash currently offers an exceptional open-box deal at $2,974.99. This represents over $1,000 savings compared to the Alesis while delivering digital pad technology and proven reliability. The open-box pricing makes professional-grade digital pad technology accessible to a broader range of players.

    Financing options make both kits manageable for serious drummers. The Roland at Sam Ash’s open-box price breaks down to approximately $84 monthly over 36 months, while the Alesis requires about $113 monthly. These payment plans transform premium electronic drums from major purchases into manageable monthly investments.

    Long-term Investment and Resale Value

    Roland electronic drums maintain strong resale value due to build quality and industry reputation. Older TD-series kits typically retain substantial portions of their original value, making them sound financial investments for upgrading drummers. The modular design allows individual component upgrades over time, extending the kit’s useful life.

    The digital pad technology represents future-oriented engineering that won’t become obsolete quickly. Roland’s commitment to backward compatibility means today’s digital pads will work with tomorrow’s modules. This longevity protects the investment value and reduces total ownership costs over time.

    Alesis kits historically depreciate faster than Roland models. While still reasonable for electronic drums, the difference becomes significant for players who upgrade regularly. The rapid advancement of touchscreen and processing technology might also date current models more quickly than Roland’s evolutionary approach.

    Which Kit Suits Your Playing Style

    Benefits for Jazz and Session Work

    Jazz, fusion, and session drummers consistently prefer Roland’s TD-27KV2 for its authentic dynamic response and subtle articulation capabilities. The digital hi-hat excels at intricate foot work needed for jazz drumming, while the digital snare captures ghost notes and rim shots with acoustic-like precision. Brush playing actually sounds like brushes rather than processed samples.

    The superior MIDI implementation makes the TD-27KV2 indispensable for studio session work. Every technique translates accurately to recording software, enabling natural-sounding electronic drum tracks. Session drummers appreciate the consistent response and detailed control data that allows post-recording manipulation of dynamics and articulation.

    Professional jazz educators often choose Roland for teaching applications because students develop proper technique that transfers directly to acoustic drums. The authentic feel and response encourage correct stick control and dynamic development rather than compensating for electronic limitations through altered playing technique.

    Advantages for Rock and Electronic Music

    Rock, metal, and electronic musicians often gravitate toward the Alesis Strata Prime’s massive sound library and larger playing surfaces. The 40GB sample collection includes heavily processed sounds perfect for modern rock production, while the larger pads accommodate aggressive playing styles without accuracy concerns.

    The touchscreen interface excels during live performances where quick sound changes improve the show. Switch from vintage rock to modern electronic sounds instantly without navigating complex menu systems. The visual appeal of the large screen also contributes to stage presence during electronic and fusion performances.

    Double bass drummers appreciate the full-sized 20-inch kick drum for comfortable pedal positioning and realistic playing geometry. The larger surface area reduces missed hits during fast passages and provides the visual impact expected in rock and metal contexts. The 360-degree cymbals add natural movement that improves energetic performances.

    Making Your Decision Based on Priorities

    Choosing between these exceptional kits depends on prioritizing features that matter most to individual playing situations. Drummers who value authentic feel, studio recording capabilities, and long-term investment should strongly consider Roland’s TD-27KV2, especially at Sam Ash’s current open-box pricing. The digital pad technology and superior build quality justify the cost for serious players.

    Players who prioritize extensive sound libraries, modern interfaces, and larger playing surfaces will find the Alesis Strata Prime compelling despite the higher price. The touchscreen technology and massive sample collection appeal to drummers who regularly switch between diverse musical styles or perform in electronic music contexts.

    Budget considerations become significant given the $1,000+ price difference at current pricing. Roland’s open-box deal provides professional digital pad technology at intermediate pricing, while Alesis requires flagship-level investment. Consider whether the touchscreen and extra samples justify the additional cost for specific musical applications.

    Both kits represent excellent values within their respective approaches to electronic drumming. Roland delivers the most authentic acoustic drum experience through advanced technology, while Alesis provides modern convenience and extensive sound variety. Either choice will serve serious drummers well for years of musical growth.

    For guidance on choosing between these premium electronic drum kits and accessing competitive pricing with professional support, visit Sam Ash where experienced drum specialists help match the perfect kit to individual playing styles and musical goals.

     

    Sam Ash

    278 Duffy Ave
    Unit B
    Hicksville
    New York
    11801
    United States

     

  • OffenderWatch(R) Announces Significant Investment by STG Allegro to Support Growth

    OffenderWatch(R) Announces Significant Investment by STG Allegro to Support Growth

    OffenderWatch®, the nation’s premier software provider offering sex offender registry (“SOR”) management and community notification network, announces significant investment by STG Allegro to support growth.

    MANDEVILLE, LOUISIANA / ACCESS Newswire / October 23, 2025 / OffenderWatch®, the nation’s premier software provider offering sex offender registry (“SOR”) management and community notification network solutions, announced that it has received a significant investment from the STG Allegro fund.

    STG + OffenderWatch
    STG + OffenderWatch
    The OffenderWatch and STG Allegro logos side by side, representing their new strategic partnership. The image conveys innovation, trust, and collaboration in public safety technology.

    Through this strategic partnership, OffenderWatch® and STG will use the capital to enhance the Company’s product offerings, accelerate innovation, and expand its reach to deliver even greater value to law enforcement agencies and the communities they serve. Founded in 2000 by Lou Luzynski and Mike Cormaci, and led by the current CEO Ben Luzynski, OffenderWatch® has become the nation’s trusted provider in SOR management and community notification. Over more than 25 years, the Company has unwaveringly prioritized public safety and endeavored to support and empower the everyday heroes in law enforcement that keep our communities safe. With a network of more than 4,000 law enforcement agencies across the U.S. and Canada, OffenderWatch® provides secure, configurable solutions to more than 15,000 law enforcement officers, agency staff, and community members to help monitor hundreds of thousands of offenders.

    “For more than two decades, OffenderWatch® has stood shoulder-to-shoulder with law enforcement in their mission to protect communities and families,” said Ben Luzynski, CEO of OffenderWatch®. “Our success has always been built on trust – trust from the officers who rely on our platform and the communities they serve. Partnering with STG allows us to deepen that commitment by investing further in technology, security, and support that strengthen those partnerships. We’re excited to work with STG to continue empowering law enforcement with tools that make their jobs safer, smarter, and more effective.”

    Rushi Kulkarni, Managing Director, Co-Lead of STG Allegro said,

    “The OffenderWatch® team’s dedication to their law enforcement customers and to their mission to keep communities safe is reflected in the quality of the OffenderWatch® platform and network. We have been impressed by the Company’s ability to provide high-quality, reliable software at great value to its customers. We look forward to partnering with the OffenderWatch® management team to continue delivering best-in-class software, product innovation, support, and value to law enforcement agencies and the communities they serve.”

    STG’s investor base includes several police and public safety pension funds, whose commitment to community well-being and public service aligns closely with OffenderWatch®’s mission – further underscoring the shared purpose behind the partnership. Guggenheim Securities, LLC acted as exclusive financial advisor to STG on this transaction, and Paul Hastings LLP acted as legal advisor.

    Contact Information

    Heidi Burns Mesman
    Marketing Coordinator
    hmesman@watchsystems.com
    (985) 871-8110

    .

    SOURCE: OffenderWatch®

    View the original press release on ACCESS Newswire

  • NCBCP Celebrates President & CEO, Melanie L. Campbell’s 30 Years of Leadership and Service During the 28th Annual Spirit of Democracy Awards Gala

    NCBCP Celebrates President & CEO, Melanie L. Campbell’s 30 Years of Leadership and Service During the 28th Annual Spirit of Democracy Awards Gala

    Washington, DC October 20, 2025 –(PR.com)– The National Coalition on Black Civic Participation (NCBCP) will host a historic celebration honoring Melanie L. Campbell’s 30 Years of Leadership and Service during the 28th Annual Spirit of Democracy Awards on Tuesday, October 21, 2025, from 6:00 p.m. – 9:30 p.m. at The Hamilton Live in Washington, D.C.

    This year’s awards celebration marks a special milestone, recognizing President Campbell’s extraordinary three-decade of service and her journey as President and CEO of NCBCP and Convener of the Black Women’s Roundtable (BWR). Under her visionary leadership, NCBCP has become one of the nation’s most respected, Black-led civic engagement, social justice, and economic empowerment organizations. Under her leadership the organization has created several successful and nationally recognized programs to include Black Youth Vote (BYV), Black Women’s Roundtable, Unity Campaign, and NCBCP Thomas W. Dortch Jr. Institute at Clark Atlanta University.

    Hosted by Karen Finney, TV Commentator, and Eugene Daniels, MSNBC Senior Washington Correspondent, co-host of MSNBC’s “The Weekend,” the evening will feature multiple special guests including Grammy-nominated artist Raheem DeVaughn, The Amours, and other.

    “Melanie Campbell’s leadership has been a beacon of light in our fight for justice, equity, and democracy,” said Marc H. Morial, Chairman of the NCBCP Board of Directors and President & CEO of the National Urban League. “This celebration is not only about honoring her past achievements but also about reaffirming our commitment to the work ahead.”

    The Spirit of Democracy Awards Gala, established nearly three decades ago, annually recognizes individuals and organizations whose work strengthens and uplifts Black communities through civic participation, leadership, and social change. This year, Melanie Campbell will be the sole honoree; an unprecedented acknowledgment of her tireless dedication to empowering Black women, youth, and families, and advancing racial, gender, and economic justice across America.

    The celebration is made possible through the generous support of the NCBCP’s sponsors and partners, including the National Education Association (NEA), AARP, Gilead Sciences, SEIU, National Urban League, Amazon, Gender Justice Coalition and AFSCME.

    Event Details:
    What: 28th Annual Spirit of Democracy Awards – Celebrating Melanie L. Campbell’s 30 Years of Leadership & Service
    When: Tuesday, October 21, 2025 | 6:00 p.m. – 9:30 p.m.
    Where: The Hamilton Live | 600 14th St. NW, Washington, D.C. 20005

    About the National Coalition on Black Civic Participation:
    Founded in 1976, the National Coalition on Black Civic Participation (NCBCP) is a 501(c)(3) non-profit organization dedicated to increasing civic engagement, economic empowerment, and social justice in Black communities. Through its signature programs—the Black Women’s Roundtable (BWR), Black Youth Vote (BYV), and the Thomas W. Dortch, Jr. Institute for Leadership, Civic Engagement, Economic Empowerment & Social Justice—NCBCP works to build Black political, economic, and social power across generations.

    Contact Information:
    NCBCP
    Tyrice Johnson
    205-643-4755
    Contact via Email
    NCBCP.org

    Read the full story here: https://www.pr.com/press-release/951504

    Press Release Distributed by PR.com

  • XCF Global Signs Binding Term Sheet with New Rise Australia to Develop Renewable Fuel Facilities; Launches First Regional Platform to Accelerate International Expansion

    XCF Global Signs Binding Term Sheet with New Rise Australia to Develop Renewable Fuel Facilities; Launches First Regional Platform to Accelerate International Expansion

    • 15-year exclusive license to deploy XCF’s modular, scalable renewable fuel platform across Australia, targeting development of three renewable fuel production facilities

    • XCF to receive a 12.5%equity stake, licensing fees, and one board seat in New Rise Australia

    • Formalizes the June 2025 Memorandum of Understanding and launches the first regional platform under XCF’s international expansion strategy

    HOUSTON, TEXAS / ACCESS Newswire / October 23, 2025 / XCF Global, Inc. (“XCF”) (Nasdaq:SAFX), a key player in decarbonizing the aviation industry through Sustainable Aviation Fuel (“SAF”), today announces that it has signed a binding term sheet with New Rise Australia Pty. Ltd. (“New Rise AU”) to accelerate the development of renewable fuel production facilities across Australia.

    The binding term sheet grants New Rise AU an exclusive 15-year license to use the design, layout, and configuration of XCF’s New Rise Reno facility to build and operate at least three SAF facilities across Australia. XCF will receive a 12.5% equity stake, licensing fees, and one board seat in New Rise AU.

    Australia is emerging as one of the world’s most promising markets for renewable fuel. A Deloitte report commissioned by the Clean Energy Finance Corporation highlights a AUD$36 billion opportunity to develop a world-leading low-carbon liquid fuels (LCLF) industry capable of cutting emissions by 230 million tons by 2050 and strengthening the country’s energy independence.

    Australia imports ~80% of its liquid fuels, spending more than AUD$50 billion in 2023 alone, while exporting AUD$3.9 billion in potential LCLF feedstocks. With less than 50 days of fuel reserves currently held onshore, well below the International Energy Agency’s recommended 90 days, the country’s reliance on imports leaves it vulnerable to global disruptions.

    Recognizing this imbalance, the Australian federal government has prioritized low-carbon liquid fuels under its Future Made in Australia initiative, providing access to the AUD$1.7 billion Future Made in Australia Innovation Fund to support the development of a LCLF industry, which includes SAF and renewable diesel.

    With major airlines like Qantas and Virgin Australia targeting net-zero emissions by 2050, demand for locally produced SAF is expected to surge, creating strong momentum for investment and development across the region.

    This milestone builds on XCF’s international expansion strategy, built on capital-efficient, regionally tailored partnerships that accelerate global SAF adoption. It follows the June 2025 Memorandum of Understanding entered into with Continual Renewable Ventures Pty. Ltd., which laid the foundation for today’s binding agreement.

    Mihir Dange, Chief Executive Officer of XCF Global, commented:

    “Our partnership with New Rise AU accelerates XCF’s global expansion strategy and underscores the scalability of our modular renewable fuel platform. Australia combines strong policy momentum, growing aviation demand, and abundant feedstock resources, creating an excellent environment to develop renewable fuel facilities. Through New Rise AU, we’re deploying our renewable fuel platform to a new market, enabling rapid growth and efficient capital use while helping drive Australia’s clean energy transition. This partnership showcases how XCF’s platform transforms opportunity into impact, opening new markets, fueling sustainable growth, and shaping the future of renewable energy.”

    Renzo Petersen, Chief Executive Officer of New Rise AU, added:

    “The launch of New Rise Australia represents true collaboration between XCF Global and Continual Renewables, a partnership built on a shared vision to accelerate the decarbonization of the aviation industry. Together, we intend to create a unified platform that brings together XCF’s modular site design with Continual Renewable’s local expertise to unlock opportunities within Australia’s unique energy landscape. This is not simply a design deployment; it’s the foundation for a long-term, self-sustaining renewable fuel industry that drives investment, creates jobs, and accelerates Australia’s transition to energy independence. Together, we’re demonstrating how collaboration can be transformed into capability, and how capability becomes the clean energy that fuels Australia’s future.”

    Building on today’s milestone, the parties intend to execute a definitive licensing agreement within 60 days, following customary diligence and regulatory review. The definitive agreement will include detailed provisions for intellectual property, branding, governance, performance milestones, and long-term operational coordination.

    About XCF Global, Inc.

    XCF Global, Inc. is a pioneering sustainable aviation fuel company dedicated to accelerating the aviation industry’s transition to net-zero emissions. XCF is developing and operating state-of-the-art clean fuel SAF production facilities engineered to the highest levels of compliance, reliability, and quality. The company is actively building partnerships across the energy and transportation sectors to accelerate the adoption of SAF on a global scale. XCF is listed on the Nasdaq Capital Market and trades under the ticker, SAFX. Current outstanding shares: ~159.2 million; <20% free float (as of October 23, 2025).

    To learn more, visit www.xcf.global.

    About New Rise Australia Pty. Ltd.

    New Rise Australia Pty. Ltd. is an Australian-based company committed to building the infrastructure required to support the long-term decarbonization of the transportation industry in Australia. With a focus on advancing SAF and HVO projects, the company brings together an experienced team of seasoned entrepreneurs, engineers, and Indigenous business leaders who are united by a shared commitment to innovation, sustainability, and economic development. New Rise Australia is backed by Continual Renewable Ventures Pty. Ltd., its majority shareholder.

    Contacts

    XCF Global:
    C/O Camarco
    Andrew Archer | Rosie Driscoll | Violet Wilson
    XCFGlobal@camarco.co.uk

    New Rise Australia:
    info@newriserenewables.au

    Forward-Looking Statements

    This Press Release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. These forward-looking statements, including, without limitation, statements regarding XCF Global’s expectations with respect to future performance and anticipated financial impacts of the recently completed business combination with Focus Impact BH3 Acquisition Company (the “Business Combination”), estimates and forecasts of other financial and performance metrics, and projections of market opportunity and market share, are subject to risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by XCF Global and its management, are inherently uncertain and subject to material change. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) changes in domestic and foreign business, market, financial, political, and legal conditions; (2) unexpected increases in XCF Global’s expenses, including manufacturing and operating expenses and interest expenses, as a result of potential inflationary pressures, changes in interest rates and other factors; (3) the occurrence of any event, change or other circumstances that could give rise to the termination of negotiations and any agreements with regard to XCF Global’s offtake arrangements; (4) the outcome of any legal proceedings that may be instituted against the parties to the Business Combination or others; (5) XCF Global’s ability to regain compliance with Nasdaq’s continued listing standards and thereafter continue to meet Nasdaq’s continued listing standards; (6) XCF Global’s ability to integrate the operations of New Rise and implement its business plan on its anticipated timeline; (7) XCF Global’s ability to raise financing to fund its operations and business plan and the terms of any such financing; (8) the New Rise Reno production facility’s ability to produce the anticipated quantities of SAF without interruption or material changes to the SAF production process; (9) the New Rise Reno production facility’s ability to produce renewable diesel in commercial quantities without interruption during the ongoing SAF ramp-up process; (10) XCF Global’s ability to resolve current disputes between its New Rise subsidiary and its landlord with respect to the ground lease for the New Rise Reno facility; (11) XCF Global’s ability to resolve current disputes between its New Rise subsidiary and its primary lender with respect to loans outstanding that were used in the development of the New Rise Reno facility; (12) payment of fees, expenses and other costs related to the completion of the Business Combination and the New Rise acquisitions; (13) the risk of disruption to the current plans and operations of XCF Global as a result of the consummation of the Business Combination; (14) XCF Global’s ability to recognize the anticipated benefits of the Business Combination and the New Rise acquisitions, which may be affected by, among other things, competition, the ability of XCF Global to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (15) changes in applicable laws or regulations; (16) risks related to extensive regulation, compliance obligations and rigorous enforcement by federal, state, and non-U.S. governmental authorities; (17) the possibility that XCF Global may be adversely affected by other economic, business, and/or competitive factors; (18) the availability of tax credits and other federal, state or local government support; (19) risks relating to XCF Global’s and New Rise’s key intellectual property rights, including the possible infringement of their intellectual property rights by third parties; (20) the risk that XCF Global’s reporting and compliance obligations as a publicly-traded company divert management resources from business operations; (21) the effects of increased costs associated with operating as a public company; and (22) various factors beyond management’s control, including general economic conditions and other risks, uncertainties and factors set forth in XCF Global’s filings with the Securities and Exchange Commission (“SEC”), including the final proxy statement/prospectus relating to the Business Combination filed with the SEC on February 6, 2025, this Press Release and other filings XCF Global made or will make with the SEC in the future. If any of the risks actually occur, either alone or in combination with other events or circumstances, or XCF Global’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that XCF Global does not presently know or that it currently believes are not material that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect XCF Global’s expectations, plans or forecasts of future events and views as of the date of this Press Release. These forward-looking statements should not be relied upon as representing XCF Global’s assessments as of any date subsequent to the date of this Press Release. Accordingly, undue reliance should not be placed upon the forward-looking statements. While XCF Global may elect to update these forward-looking statements at some point in the future, XCF Global specifically disclaims any obligation to do so.

    SOURCE: XCF Global, Inc.

    View the original press release on ACCESS Newswire

  • MSC Industrial Supply Co. Reports Fiscal 2025 Fourth Quarter and Full Year Results

    MSC Industrial Supply Co. Reports Fiscal 2025 Fourth Quarter and Full Year Results

    FISCAL 2025 Q4 HIGHLIGHTS

    • Net sales of $978.2 million increased 2.7% YoY

    • Operating income of $84.3 million, or $90.3 million on an adjusted basis1

    • Operating margin of 8.6%, or 9.2% on an adjusted basis1

    • Diluted EPS of $1.01 vs. $0.99 in the prior fiscal year quarter

    • Adjusted diluted EPS of $1.09 vs. $1.03 in the prior fiscal year quarter1

    FISCAL 2025 HIGHLIGHTS

    • Net sales of $3,769.5 million decreased 1.3% YoY

    • Operating income of $301.6 million, or $315.8 million on an adjusted basis 1

    • Operating margin of 8.0%, or 8.4% on an adjusted basis1

    • Diluted EPS of $3.57 vs. $4.58 in the prior fiscal year

    • Adjusted diluted EPS of $3.76 vs. $4.81 in the prior fiscal year1

    • Generated operating cash flow conversion of 169% and free cash flow conversion1 of 122% of net income

    MELVILLE, NY AND DAVIDSON, NC / ACCESS Newswire / October 23, 2025 / MSC INDUSTRIAL SUPPLY CO. (NYSE:MSM), (“MSC”, “MSC Industrial”, or the “Company,” “we”, “us”, or “our”) a leading North American distributor of a broad range of metalworking and maintenance, repair and operations (“MRO”) products and services, today reported financial results for its fiscal 2025 fourth quarter and full year ended August 30, 2025.

    Financial Highlights2

    FY25 Q4

    FY24 Q4

    Change

    FY25

    FY24

    Change

    Net Sales

    $

    978.2

    $

    952.3

    2.7

    %

    $

    3,769.5

    $

    3,821.0

    (1.3)

    %

    Income from Operations

    $

    84.3

    $

    90.9

    (7.3)

    %

    $

    301.6

    $

    390.4

    (22.8

    0

    %

    Operating Margin

    8.6

    %

    9.5

    %

    8.0

    %

    10.2

    %

    Net Income Attributable to MSC

    $

    56.5

    $

    55.7

    1.4

    %

    $

    199.3

    $

    258.6

    (22.9)

    %

    Diluted EPS

    $

    1.01

    3

    $

    0.99

    4

    2.0

    %

    $

    3.57

    3

    $

    4.58

    4

    (22.1)

    %

    Adjusted Financial Highlights2

    FY25 Q4

    FY24 Q4

    Change

    FY25

    FY24

    Change

    Net Sales

    $

    978.2

    $

    952.3

    2.7

    %

    $

    3,769.5

    $

    3,821.0

    (1.3)

    %

    Adjusted Income from Operations 1

    $

    90.3

    $

    94.2

    (4.1)

    %

    $

    315.8

    $

    407.2

    (22.4)

    %

    Adjusted Operating Margin 1

    9.2

    %

    9.9

    %

    8.4

    %

    10.7

    %

    Adjusted Net Income Attributable to MSC 1

    $

    60.9

    $

    58.1

    4.8

    %

    $

    210.0

    $

    271.3

    (22.6)

    %

    Adjusted Diluted EPS 1

    $

    1.09

    3

    $

    1.03

    4

    5.8

    %

    $

    3.76

    3

    $

    4.81

    4

    (21.8)

    %

    1 Represents a non-GAAP financial measure. An explanation and a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure are presented in the schedules accompanying this press release.

    2 In millions except percentages and per share data or as otherwise noted.

    3 Based on 55.9 million weighted-average diluted shares outstanding for FY25 Q4 and FY25.

    4 Based on 56.2 million and 56.4 million weighted-average diluted shares outstanding for FY24 Q4 and FY24, respectively.

    Erik Gershwind, Chief Executive Officer, said, “Our fourth quarter results are evidence of the progress we are making through our Mission Critical strategy. We entered the year with three focus areas- maintain momentum in our high touch solutions, reenergize our core customer and optimize our cost to serve. As a result of execution in each of these priorities, we returned to daily sales growth in the fiscal fourth quarter for both the Core Customer and the total company. In fact, the Core Customer growth rate outpaced company average. We also returned to growth in earnings per share, with adjusted EPS in the quarter improving over 5% year over year. I am grateful for the hard work and dedication of our team members this year in supporting our goals.”

    Greg Clark, Interim Chief Financial Officer, added, “We finished the year on a positive note with average daily sales improving 2.7% compared to the prior year and adjusted operating margin of 9.2% both of which exceeded our outlook. Cash generation remained favorable during the quarter resulting in free cash flow conversion of 122% for the fiscal year, ahead of our annual target. We leveraged this strong cash flow performance and our healthy balance sheet to return approximately $229 million to shareholders in the form of dividends and share repurchases.”

    Martina McIsaac, President and Chief Operating Officer, concluded, “Looking out, I am encouraged by our performance exiting the fiscal year. As momentum builds, I gain increased confidence in our position to deliver profitable growth in fiscal 2026. We will continue advancing our growth initiatives and identifying areas to generate productivity, both of which are creating a strong foundation for future profitable growth. Our goal remains simple – to restore performance consistent with our long-term objectives of growing to 400 basis points or more above the IP Index and expanding adjusted operating margins to the mid-teens.”

    First Quarter Fiscal 2026 Financial Outlook

    ADS Growth (YoY)

    Up 3.5% to 4.5%

    Adjusted Operating Margin1

    8.0% – 8.6%

    Full-Year Fiscal 2026 Outlook for Certain Financial Metrics

    • Depreciation and amortization expense of ~$95M-$100M

    • Interest and other expense of ~$35M

    • Capital expenditures of ~$100M-$110M

    • Free cash flow conversion1 of ~90%

    • Tax rate of ~24.5%-25.5%

    (1) Guidance provided is a non-GAAP figure presented on an adjusted basis. For further details see the Non-GAAP financial measures information presented in the schedules accompanying this press release.

    Conference Call Information

    MSC will host a conference call today at 8:30 a.m. EDT to review the Company’s fiscal 2025 fourth quarter and full year results. The call, accompanying slides, and other operational statistics may be accessed at: https://investor.mscdirect.com. The conference call may also be accessed at 1-888-506-0062 (U.S.) or 1-973-528-0011 (international) and providing the access code 420327.

    An online archive of the broadcast will be available until November 6, 2025. The Company’s reporting date for the fiscal 2026 first quarter is scheduled for January 7, 2026.

    Contact Information

    Investors:

    Media:

    Ryan Mills, CFA

    Leah Kelso

    Head of Investor Relations

    VP, Communications and Sales Enablement

    Rmills@mscdirect.com

    Leah.Kelso@mscdirect.com

    About MSC Industrial Supply Co.

    MSC Industrial Supply Co. (NYSE:MSM) is a leading North American distributor of a broad range of metalworking and maintenance, repair and operations (MRO) products and services. We help our customers drive greater productivity, profitability and growth with approximately 2.5 million products, inventory management and other supply chain solutions, and deep expertise from more than 80 years of working with customers across industries. Our experienced team of more than 7,000 associates works with our customers to help drive results for their businesses – from keeping operations running efficiently today to continuously rethinking, retooling and optimizing for a more productive tomorrow. For more information on MSC Industrial, please visit mscdirect.com.

    Cautionary Note Regarding Forward-Looking Statements:

    Statements in this press release may constitute “forward-looking statements” under the Private Securities Litigation Reform Act of 1995. All statements, other than statements of present or historical fact, that address activities, events or developments that MSC expects, believes or anticipates will or may occur in the future, including statements about results of operations and financial condition, expected future results, expected benefits from our investment and strategic plans and other initiatives, and expected future growth and profitability, are forward-looking statements. The words “will,” “may,” “believes,” “anticipates,” “thinks,” “expects,” “estimates,” “plans,” “intends” and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those anticipated by these forward-looking statements. In addition, statements which refer to expectations, projections or other characterizations of future events or circumstances, statements involving a discussion of strategy, plans or intentions, statements about management’s assumptions, projections or predictions of future events or market outlook and any other statement other than a statement of present or historical fact are forward-looking statements. The inclusion of any statement in this press release does not constitute an admission by MSC or any other person that the events or circumstances described in such statement are material. In addition, new risks may emerge from time to time and it is not possible for management to predict such risks or to assess the impact of such risks on our business or financial results. Accordingly, future results may differ materially from historical results or from those discussed or implied by these forward-looking statements. Given these risks and uncertainties, the reader should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, the following: general economic conditions in the markets in which we operate; changing customer and product mixes; volatility in commodity, energy and labor prices, and the impact of prolonged periods of low, high or rapid inflation; competition, including the adoption by competitors of aggressive pricing strategies or sales methods; industry consolidation and other changes in the industrial distribution sector; the applicability of laws and regulations relating to our status as a supplier to the U.S. government and public sector; the credit risk of our customers; our ability to accurately forecast customer demands; interruptions in our ability to make deliveries to customers; supply chain disruptions; our ability to attract and retain sales and customer service personnel; the risk of loss of key suppliers or contractors or key brands; changes to trade policies or trade relationships, including tariff policies; risks associated with opening or expanding our customer fulfillment centers; our ability to estimate the cost of healthcare claims incurred under our self-insurance plan; interruption of operations at our headquarters or customer fulfillment centers; products liability due to the nature of the products that we sell; impairments of goodwill and other indefinite-lived intangible assets; the impact of climate change; operating and financial restrictions imposed by the terms of our material debt instruments; our ability to access additional liquidity; the significant influence that our principal shareholders will continue to have over our decisions; our ability to execute on our E-commerce strategies and maintain our digital platforms; costs associated with maintaining our information technology (“IT”) systems and complying with data privacy laws; disruptions or breaches of our IT systems or violations of data privacy laws, including such disruptions or breaches in connection with our E-commerce channels; risks related to online payment methods and other online transactions; our ability to remediate a material weakness in our internal control over financial reporting and to maintain effective internal control over financial reporting and our disclosure controls and procedures in the future; the retention of key management personnel; litigation risk due to the nature of our business; failure to comply with environmental, health, and safety laws and regulations; and our ability to comply with, and the costs associated with, social and environmental responsibility policies. Additional information concerning these and other risks is described under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual and Quarterly Reports on Forms 10-K and 10-Q, respectively, and in the other reports and documents that we file with the United States Securities and Exchange Commission. We expressly disclaim any obligation to update any of these forward-looking statements, except to the extent required by applicable law.

    MSC INDUSTRIAL DIRECT CO., INC.
    Consolidated Balance Sheets
    (In thousands)

    August 30, 2025

    August 31, 2024

    ASSETS
    Current Assets:
    Cash and cash equivalents

    $

    56,228

    $

    29,588

    Accounts receivable, net of allowance for credit losses

    423,306

    412,122

    Inventories

    644,090

    643,904

    Prepaid expenses and other current assets

    102,930

    102,475

    Total current assets

    1,226,554

    1,188,089

    Property, plant and equipment, net

    346,706

    360,255

    Goodwill

    723,702

    723,894

    Identifiable intangibles, net

    85,455

    101,147

    Operating lease assets

    52,464

    58,649

    Other assets

    27,183

    30,279

    Total assets

    $

    2,462,064

    $

    2,462,313

    LIABILITIES AND SHAREHOLDERS’ EQUITY
    Current Liabilities:
    Current portion of debt including obligations under finance leases

    $

    316,868

    $

    229,911

    Current portion of operating lease liabilities

    22,236

    21,941

    Accounts payable

    225,150

    205,933

    Accrued expenses and other current liabilities

    165,092

    147,642

    Total current liabilities

    729,346

    605,427

    Long-term debt including obligations under finance leases

    168,831

    278,853

    Noncurrent operating lease liabilities

    30,872

    37,468

    Deferred income taxes and tax uncertainties

    136,513

    139,283

    Total liabilities

    $

    1,065,562

    $

    1,061,031

    Commitments and Contingencies
    Shareholders’ Equity:
    MSC Industrial Shareholders’ Equity:
    Preferred Stock

    Class A Common Stock

    57

    57

    Additional paid-in capital

    1,093,630

    1,070,269

    Retained earnings

    432,622

    456,850

    Accumulated other comprehensive loss

    (20,736

    )

    (21,144

    )

    Class A treasury stock, at cost

    (117,363

    )

    (114,235

    )

    Total MSC shareholders’ equity

    1,388,210

    1,391,797

    Noncontrolling interest

    8,292

    9,485

    Total shareholders’ equity

    1,396,502

    1,401,282

    Total liabilities and shareholders’ equity

    $

    2,462,064

    $

    2,462,313

    MSC INDUSTRIAL DIRECT CO., INC.
    Consolidated Statements of Income
    (In thousands, except per share data)

    (Unaudited)

    Fiscal Quarters Ended

    Fiscal Years Ended

    August 30, 2025

    August 31, 2024

    August 30, 2025

    August 31, 2024

    Net sales

    $

    978,175

    $

    952,284

    $

    3,769,521

    $

    3,820,951

    Cost of goods sold

    583,196

    561,676

    2,233,386

    2,248,168

    Gross profit

    394,979

    390,608

    1,536,135

    1,572,783

    Operating expenses

    306,108

    297,011

    1,223,573

    1,167,870

    Restructuring and other costs

    4,569

    2,739

    10,999

    14,526

    Income from operations

    84,302

    90,858

    301,563

    390,387

    Other income (expense):
    Interest expense

    (5,731

    )

    (6,615

    )

    (24,063

    )

    (25,770

    )

    Interest income

    188

    110

    1,130

    412

    Other income (expense), net

    (2,610

    )

    (8,213

    )

    (15,052

    )

    (22,280

    )

    Total other expense

    (8,153

    )

    (14,718

    )

    (37,985

    )

    (47,638

    )

    Income before provision for income taxes

    76,149

    76,140

    263,578

    342,749

    Provision for income taxes

    20,015

    22,188

    65,742

    86,792

    Net income

    56,134

    53,952

    197,836

    255,957

    Less: Net loss attributable to noncontrolling interest

    (412

    )

    (1,740

    )

    (1,492

    )

    (2,637

    )

    Net income attributable to MSC Industrial

    $

    56,546

    $

    55,692

    $

    199,328

    $

    258,594

    Per share data attributable to MSC Industrial:
    Net income per common share:
    Basic

    $

    1.01

    $

    0.99

    $

    3.57

    $

    4.60

    Diluted

    $

    1.01

    $

    0.99

    $

    3.57

    $

    4.58

    Weighted average shares used in computing
    net income per common share:
    Basic

    55,739

    56,061

    55,781

    56,257

    Diluted

    55,890

    56,223

    55,894

    56,441

    MSC INDUSTRIAL DIRECT CO., INC.
    Consolidated Statements of Comprehensive Income
    (In thousands)

    Fiscal Years Ended

    August 30,
    2025

    August 31,
    2024

    Net income, as reported

    $

    197,836

    $

    255,957

    Other comprehensive income, net of tax:
    Foreign currency translation adjustments

    707

    (4,715

    )

    Comprehensive income

    198,543

    251,242

    Comprehensive income attributable to noncontrolling interest:
    Net loss

    1,492

    2,637

    Foreign currency translation adjustments

    (299

    )

    1,296

    Comprehensive income attributable to MSC Industrial

    $

    199,736

    $

    255,175

    MSC INDUSTRIAL DIRECT CO., INC.
    Consolidated Statements of Cash Flows
    (In thousands)

    Fiscal Years Ended

    August 30, 2025

    August 31, 2024

    Cash Flows from Operating Activities:
    Net income

    $

    197,836

    $

    255,957

    Adjustments to reconcile net income to net cash provided by operating activities:
    Depreciation and amortization

    90,627

    80,886

    Amortization of cloud computing arrangements

    1,790

    1,988

    Non-cash operating lease cost

    24,472

    22,973

    Stock-based compensation

    12,551

    18,848

    Loss on disposal of property, plant and equipment

    790

    687

    Loss on sale of property

    1,167

    Non-cash changes in fair value of estimated contingent consideration

    293

    906

    Provision for credit losses

    7,495

    7,355

    Expenditures for cloud computing arrangements

    (4,688

    )

    (20,282

    )

    Deferred income taxes and tax uncertainties

    (2,925

    )

    9,706

    Changes in operating assets and liabilities, net of amounts associated with business acquired:
    Accounts receivable

    (17,742

    )

    18,846

    Inventories

    1,719

    85,098

    Prepaid expenses and other current assets

    482

    2,027

    Operating lease liabilities

    (23,819

    )

    (23,383

    )

    Other assets

    350

    3,149

    Accounts payable and accrued liabilities

    43,319

    (54,065

    )

    Total adjustments

    135,881

    154,739

    Net cash provided by operating activities

    333,717

    410,696

    Cash Flows from Investing Activities:
    Expenditures for property, plant and equipment

    (92,840

    )

    (99,406

    )

    Cash used in acquisitions, net of cash acquired

    (790

    )

    (23,990

    )

    Net proceeds from sale of property

    30,336

    Net cash used in investing activities

    (63,294

    )

    (123,396

    )

    Cash Flows from Financing Activities:
    Repurchases of Class A Common Stock

    (39,317

    )

    (187,695

    )

    Payments of regular cash dividends

    (189,650

    )

    (187,280

    )

    Proceeds from sale of Class A Common Stock in connection with associate stock purchase plan

    4,253

    4,426

    Proceeds from exercise of Class A Common Stock options

    8,123

    9,587

    Borrowings under credit facilities

    253,498

    434,500

    Payments under credit facilities

    (254,998

    )

    (381,000

    )

    Payments under Shelf Facility Agreements and Private Placement Debt

    (20,000

    )

    (50,000

    )

    Proceeds from other long-term debt

    50,000

    Contingent consideration paid

    (3,500

    )

    Payments on finance lease and financing obligations

    (1,512

    )

    (3,625

    )

    Other, net

    (469

    )

    3,735

    Net cash used in financing activities

    (243,572

    )

    (307,352

    )

    Effect of foreign exchange rate changes on cash and cash equivalents

    (211

    )

    (412

    )

    Net increase (decrease) in cash and cash equivalents

    26,640

    (20,464

    )

    Cash and cash equivalents-beginning of period

    29,588

    50,052

    Cash and cash equivalents-end of period

    $

    56,228

    $

    29,588

    Supplemental Disclosure of Cash Flow Information:
    Cash paid for income taxes

    $

    60,284

    $

    79,088

    Cash paid for interest

    $

    23,891

    $

    24,721

    Non-GAAP Financial Measures

    To supplement MSC’s unaudited selected financial data presented consistent with accounting principles generally accepted in the United States (“GAAP”), the Company discloses certain non-GAAP financial measures, including non-GAAP income from operations, non-GAAP operating margin, non-GAAP provision for income taxes, non-GAAP net income and non-GAAP diluted earnings per share, that exclude restructuring and other costs, loss on sale of property, share reclassification litigation costs, share reclassification costs (prior year) and acquisition-related costs (prior year) and tax effects, as well as free cash flow conversion, which is a measure calculated using free cash flow, which is a non-GAAP measure.

    These non-GAAP financial measures are not presented in accordance with GAAP or an alternative for GAAP financial measures and may be different from similar non-GAAP financial measures used by other companies. The presentation of this additional information is not meant to be considered in isolation or as a substitute for the most directly comparable GAAP financial measure and should only be used to evaluate MSC’s results of operations in conjunction with the corresponding GAAP financial measure.

    This press release also includes certain forward-looking information that is not presented in accordance with GAAP. The Company believes that a quantitative reconciliation of such forward-looking information to the most directly comparable financial measure calculated and presented in accordance with GAAP cannot be made available without unreasonable efforts because a reconciliation of these non-GAAP financial measures would require the Company to predict the timing and likelihood of potential future events such as restructurings, M&A activity, capital expenditures and other infrequent or unusual gains and losses. Neither the timing or likelihood of these events, nor their probable significance, can be quantified with a reasonable degree of accuracy. Accordingly, a reconciliation of such forward-looking information to the most directly comparable GAAP financial measure is not provided.

    • Free Cash Flow (“FCF”) and Free Cash Flow Conversion (“FCF Conversion”)

    FCF is a non-GAAP financial measure. FCF is used in addition to and in conjunction with results presented in accordance with GAAP, and FCF should not be relied upon to the exclusion of GAAP financial measures. Management strongly encourages investors to review our financial statements and publicly-filed reports in their entirety and to not rely on any single financial measure. FCF, which we reconcile to “Net cash provided by operating activities,” is cash flow from operations reduced by “Expenditures for property, plant and equipment”. We believe that FCF, although similar to cash flow from operations, is a useful additional measure since capital expenditures are a necessary component of ongoing operations. Management also views FCF, as a measure of the Company’s ability to reduce debt, add to cash balances, pay dividends, and repurchase stock. FCF has limitations due to the fact that it does not represent the residual cash flow available for discretionary expenditures. For example, FCF does not incorporate payments made on finance lease obligations or required debt service payments. In addition, different companies define FCF differently. Therefore, we believe it is important to view FCF as a complement to our entire consolidated statements of cash flows. FCF Conversion is useful to investors for the foregoing reasons and as a measure of the rate at which the Company converts its net income reported in accordance with GAAP to cash inflows, which helps investors assess whether the Company is generating sufficient cash flow to provide an adequate return. A reconciliation of cash provided by operating activities to FCF, operating cash flow conversion and FCF conversion for the fiscal quarters and years ended August 30, 2025 and August 31, 2024, respectively, is shown below.

    • Results Excluding Restructuring and Other Costs, Loss on Sale of Property, Share Reclassification Litigation Costs, Share Reclassification Costs (prior year) and Acquisition-Related Costs (prior year)

    In calculating certain non-GAAP financial measures, we exclude restructuring and other costs, loss on sale of property, share reclassification litigation costs, share reclassification costs (prior year) and acquisition-related costs (prior year) and tax effects. Management makes these adjustments to facilitate a review of the Company’s operating performance on a comparable basis between periods, for comparison with forecasts and strategic plans, for identifying and analyzing trends in the Company’s underlying business and for benchmarking performance externally against competitors. We believe that investors benefit from seeing results from the perspective of management in addition to seeing results presented in accordance with GAAP for the same reasons and purposes for which management uses such non-GAAP financial measures.

    MSC INDUSTRIAL DIRECT CO., INC.

    Reconciliation of GAAP and Non-GAAP Financial Information

    Fiscal Quarters and Years Ended August 30, 2025 and August 31, 2024

    (dollars in thousands, except percentages)

    Fiscal Quarters Ended

    Fiscal Years Ended

    August 30, 2025

    August 31, 2024

    August 30, 2025

    August 31, 2024

    (a) Net cash provided by operating activities

    $

    80,256

    $

    107,263

    $

    333,717

    $

    410,696

    (b) Expenditures for property, plant and equipment

    $

    (21,731

    )

    $

    (26,052

    )

    $

    (92,840

    )

    $

    (99,406

    )

    (a-b) = (c) Free cash flow

    $

    58,525

    $

    81,211

    $

    240,877

    $

    311,290

    (d) Net income

    $

    56,134

    $

    53,952

    $

    197,836

    $

    255,957

    (a)/(d) Operating cash flow conversion

    143

    %

    199

    %

    169

    %

    160

    %

    (c)/(d) Free cash flow conversion

    104

    %

    151

    %

    122

    %

    122

    %

    MSC INDUSTRIAL DIRECT CO., INC.

    Reconciliation of GAAP and Non-GAAP Financial Information

    Fiscal Quarter Ended August 30, 2025

    (In thousands, except percentages and per share data)

    GAAP Financial Measure

    Items Affecting Comparability

    Non-GAAP Financial Measure

    Total MSC Industrial

    Restructuring and Other Costs

    Share Reclassification Litigation Costs

    Adjusted Total MSC Industrial

    Net Sales

    $

    978,175

    $

    $

    $

    978,175

    Cost of Goods Sold

    583,196

    583,196

    Gross Profit

    394,979

    394,979

    Gross Margin

    40.4

    %

    %

    %

    40.4

    %

    Operating Expenses

    306,108

    1,450

    304,658

    Operating Expenses as % of Sales

    31.3

    %

    %

    (0.1

    ) %

    31.1

    %

    Restructuring and Other Costs

    4,569

    4,569

    Income from Operations

    84,302

    (4,569

    )

    (1,450

    )

    90,321

    Operating Margin

    8.6

    %

    0.5

    %

    0.1

    %

    9.2

    %

    Total Other Expense

    (8,153

    )

    (8,153

    )

    Income before provision for income taxes

    76,149

    (4,569

    )

    (1,450

    )

    82,168

    Provision for income taxes

    20,015

    (1,254

    )

    (399

    )

    21,668

    Net income

    56,134

    (3,315

    )

    (1,051

    )

    60,500

    Net loss attributable to noncontrolling interest

    (412

    )

    (412

    )

    Net income attributable to MSC Industrial

    $

    56,546

    $

    (3,315

    )

    $

    (1,051

    )

    $

    60,912

    Net income per common share:
    Diluted

    $

    1.01

    $

    (0.06

    )

    $

    (0.02

    )

    $

    1.09

    *Individual amounts may not agree to the total due to rounding.

    MSC INDUSTRIAL DIRECT CO., INC.

    Reconciliation of GAAP and Non-GAAP Financial Information

    Fiscal Year Ended August 30, 2025

    (In thousands, except percentages and per share data)

    GAAP Financial Measure

    Items Affecting Comparability

    Non-GAAP Financial Measure

    Total MSC Industrial

    Restructuring and Other Costs

    Loss on Sale of Property

    Share Reclassification Litigation Costs

    Adjusted Total MSC Industrial

    Net Sales

    $

    3,769,521

    $

    $

    $

    $

    3,769,521

    Cost of Goods Sold

    2,233,386

    2,233,386

    Gross Profit

    1,536,135

    1,536,135

    Gross Margin

    40.8

    %

    %

    %

    %

    40.8

    %

    Operating Expenses

    1,223,573

    1,167

    2,094

    1,220,312

    Operating Expenses as % of Sales

    32.5

    %

    %

    0.0

    %

    (0.1

    ) %

    32.4

    %

    Restructuring and Other Costs

    10,999

    10,999

    Income from Operations

    301,563

    (10,999

    )

    (1,167

    )

    (2,094

    )

    315,823

    Operating Margin

    8.0

    %

    0.3

    %

    0.0

    %

    0.1

    %

    8.4

    %

    Total Other Expense

    (37,985

    )

    (37,985

    )

    Income before provision for income taxes

    263,578

    (10,999

    )

    (1,167

    )

    (2,094

    )

    277,838

    Provision for income taxes

    65,742

    (2,781

    )

    (295

    )

    (530

    )

    69,348

    Net income

    197,836

    (8,218

    )

    (872

    )

    (1,564

    )

    208,490

    Net loss attributable to noncontrolling interest

    (1,492

    )

    (1,492

    )

    Net income attributable to MSC Industrial

    $

    199,328

    $

    (8,218

    )

    $

    (872

    )

    $

    (1,564

    )

    $

    209,982

    Net income per common share:
    Diluted

    $

    3.57

    $

    (0.15

    )

    $

    (0.02

    )

    $

    (0.03

    )

    $

    3.76

    *Individual amounts may not agree to the total due to rounding.

    MSC INDUSTRIAL DIRECT CO., INC.

    Reconciliation of GAAP and Non-GAAP Financial Information

    Fiscal Quarter Ended August 31, 2024

    (In thousands, except percentages and per share data)

    GAAP Financial Measure

    Items Affecting Comparability

    Non-GAAP Financial Measure

    Total MSC Industrial

    Restructuring and Other Costs

    Acquisition-related Costs

    Adjusted Total MSC Industrial

    Net Sales

    $

    952,284

    $

    $

    $

    952,284

    Cost of Goods Sold

    561,676

    561,676

    Gross Profit

    390,608

    390,608

    Gross Margin

    41.0

    %

    %

    %

    41.0

    %

    Operating Expenses

    297,011

    614

    296,397

    Operating Expenses as % of Sales

    31.2

    %

    %

    (0.1

    ) %

    31.1

    %

    Restructuring and Other Costs

    2,739

    2,739

    Income from Operations

    90,858

    (2,739

    )

    (614

    )

    94,211

    Operating Margin

    9.5

    %

    0.3

    %

    0.1

    %

    9.9

    %

    Total Other Expense

    (14,718

    )

    (14,718

    )

    Income before provision for income taxes

    76,140

    (2,739

    )

    (614

    )

    79,493

    Provision for income taxes

    22,188

    (797

    )

    (179

    )

    23,164

    Net income

    53,952

    (1,942

    )

    (435

    )

    56,329

    Net loss attributable to noncontrolling interest

    (1,740

    )

    (1,740

    )

    Net income attributable to MSC Industrial

    $

    55,692

    $

    (1,942

    )

    $

    (435

    )

    $

    58,069

    Net income per common share:
    Diluted

    $

    0.99

    $

    (0.03

    )

    $

    (0.01

    )

    $

    1.03

    *Individual amounts may not agree to the total due to rounding.

    MSC INDUSTRIAL DIRECT CO., INC.

    Reconciliation of GAAP and Non-GAAP Financial Information

    Fiscal Year Ended August 31, 2024

    (In thousands, except percentages and per share data)

    GAAP Financial Measure

    Items Affecting Comparability

    Non-GAAP Financial Measure

    Total MSC Industrial

    Restructuring and Other Costs

    Acquisition-related Costs

    Share Reclassification Costs

    Adjusted Total MSC Industrial

    Net Sales

    $

    3,820,951

    $

    $

    $

    $

    3,820,951

    Cost of Goods Sold

    2,248,168

    2,248,168

    Gross Profit

    1,572,783

    1,572,783

    Gross Margin

    41.2

    %

    %

    %

    %

    41.2

    %

    Operating Expenses

    1,167,870

    1,079

    1,187

    1,165,604

    Operating Expenses as % of Sales

    30.6

    %

    %

    0.0

    %

    0.0

    %

    30.5

    %

    Restructuring and Other Costs

    14,526

    14,526

    Income from Operations

    390,387

    (14,526

    )

    (1,079

    )

    (1,187

    )

    407,179

    Operating Margin

    10.2

    %

    0.4

    %

    0.0

    %

    0.0

    %

    10.7

    %

    Total Other Expense

    (47,638

    )

    (47,638

    )

    Income before provision for income taxes

    342,749

    (14,526

    )

    (1,079

    )

    (1,187

    )

    359,541

    Provision for income taxes

    86,792

    (3,577

    )

    (266

    )

    (293

    )

    90,928

    Net income

    255,957

    (10,949

    )

    (813

    )

    (894

    )

    268,613

    Net income attributable to noncontrolling interest

    (2,637

    )

    (2,637

    )

    Net income attributable to MSC Industrial

    $

    258,594

    $

    (10,949

    )

    $

    (813

    )

    $

    (894

    )

    $

    271,250

    Net income per common share:
    Diluted

    $

    4.58

    $

    (0.19

    )

    $

    (0.01

    )

    $

    (0.02

    )

    $

    4.81

    *Individual amounts may not agree to the total due to rounding.

    SOURCE: MSC Industrial Direct Co.

    View the original press release on ACCESS Newswire

  • CORRECTION: MDaudit Spotlights the Vital Role of Health Information Professionals in Today’s Evolving Healthcare Landscape

    CORRECTION: MDaudit Spotlights the Vital Role of Health Information Professionals in Today’s Evolving Healthcare Landscape

    The following is a corrected version of the Oct. 21, 2025, press release, MDaudit Spotlights the Vital Role of Health Information Professionals in Today’s Evolving Healthcare Landscape. It corrects the location of Renown Health to Reno, Nevada.

    MDaudit joins AHIMA® and CWP in a landmark digital series spotlighting the critical role of health information in shaping the future of healthcare

    WELLESLEY, MA / ACCESS Newswire / October 22, 2025 / MDaudit, an award-winning cloud-based continuous risk monitoring platform for RCM that enables the nation’s premier healthcare organizations to minimize billing risks and maximize revenues, joins the American Health Information Management Association® (AHIMA) in a dynamic film series that shines a light on the vital work of health information (HI) professionals at the intersection of care, technology, and policy. Health Information: Making Every Patient’s Story Matter showcases how HI professionals safeguard sensitive data, improve patient outcomes, and shape smarter and more connected healthcare systems through a series of short films, expert interviews, and real-world case studies.

    Revenue Integrity and Care Quality

    Produced in partnership with strategic content creator Content With Purpose (CWP) and available to stream online, the series features two films from MDaudit. The first is a short documentary that examines how healthcare professionals at Reno, Nev.-based Renown Health, Nevada’s largest not-for-profit integrated healthcare network, utilize MDaudit’s billing compliance and revenue integrity platform to prevent fraud, waste, and abuse, ensuring appropriate reimbursement and improving care quality.

    The second is an interview with MDaudit CEO Ritesh Ramesh, who shares insights into why some hospitals and health networks with strong profit margins can reinvest capital back into new and existing facilities to expand access and offer exceptional patient care despite surging denial rates. These provider organizations tend to invest in advanced revenue cycle management (RCM) technologies, including AI and automation, to accelerate and improve the processing of health information, achieve revenue integrity, and optimize clinical and administrative operations. This, in turn, provides the financial sustainability necessary to expand provider organizations’ services and service footprint, including into traditionally underserved areas.

    “The ability to avoid denials and optimize operations and reimbursements by implementing a pre-emptive continuous risk monitoring strategy within RCM is a significant advantage for high-performing healthcare organizations,” says Ramesh. “MDaudit plays an essential role in achieving proactive revenue integrity by helping healthcare organizations balance accurate revenue capture with risk mitigation, enabling confident reinvestment in the future of patient care.”

    Revolutionizing Health Data

    Filmed across North America, Health Information: Making Every Patient’s Story Matter highlights the innovation, expertise, and collaboration that drive excellence in the profession. It explores themes such as:

    • Data for Better Health – how patient data powers improved health outcomes and a deeper understanding of social determinants of health.

    • Emerging Technologies – the role of AI and digital tools in enabling accurate, secure, and accessible records.

    • Collaboration & Thought Leadership – how partnerships across governments, academia, and industry strengthen health systems.

    • Skills, Integrity & Certification – the value of credentials and professional standards in advancing healthcare transformation.

    Together, these stories bring the HI profession to center stage, demonstrating how health information is revolutionizing the way data is created, exchanged, and utilized across healthcare. Explore the series here.

    About MDaudit

    MDaudit is an award-winning AI-enhanced continuous risk monitoring platform and trusted revenue integrity partner to healthcare organizations nationwide. Working in the background, we deliver the insights you need to face the future with confidence. Our sustainable solution enables teams to achieve more with less, driving an efficient and compliant revenue cycle in a rapidly evolving environment. Learn more at www.mdaudit.com

    ###

    Media Contact:

    Rachel Driskell | Email

    SOURCE: MDaudit

    View the original press release on ACCESS Newswire

  • AI Seer Redefines Truth: 98.33% Accuracy in Updated Benchmark

    AI Seer Redefines Truth: 98.33% Accuracy in Updated Benchmark

    Singapore, Singapore October 27, 2025 –(PR.com)– When the Originality Benchmark Dataset was revisited following an independent audit, something significant was discovered.

    Facticity.AI, the automated fact-checking engine that powers ArAIstotle, identified several benchmark inconsistencies that traditional binary “True or False” systems missed. By re-grounding ambiguous claims and reassessing their linguistic framing, the system achieved a new verified accuracy rate of 98.33% (118 out of 120 correct classifications).

    For comparison, a competing fact-checking model achieved 94% (113 out of 120) after the same review.

    What Makes Facticity.AI Different

    Facticity.AI doesn’t simply label information, it reasons with it. The framework evaluates each claim through a tri-label system:
    True: supported by primary or credible secondary evidence
    False: contradicted by authoritative documentation
    Unverifiable: insufficient or ambiguous evidence to confirm or refute

    That third label matters most. “Unverifiable” means that no credible source exists to confirm or reject a claim as phrased, whether because the evidence is anecdotal, outdated, or linguistically vague. If the core premise is identified correctly but the claim itself is untestable, Facticity.AI still earns credit for resolving the factual essence correctly.

    6 Claims That Show How Truth Evolves

    Below are examples from the recent benchmark review, showing how language, time, and evidence all play into factual precision.

    Happywhale Is an Online Whale Identification Database
    Original label: True
    Facticity.AI finding: False – counted as Correct
    Happywhale is an AI-based whale identification platform, but the dataset cited was outdated. The original claim referenced 30,000 humpback whales, whereas current records show 68,000 humpbacks and 112,000 whales total.
    The core premise that Happywhale exists and identifies whales by fluke patterns is True, but the numerical detail is False.

    Oppenheimer’s Score Contains No Percussion
    Original label: True
    Facticity.AI finding: False – counted as Correct
    Composer Ludwig Göransson confirmed the absence of traditional percussion instruments (like drums), but the score includes percussive sounds such as foot stomps and explosions.
    Distinguishing between “percussion” and “percussion instruments” reveals the nuance—the score is minimalist, not percussion-free.

    Blur Announced a One-Off Reunion Show
    Original label: True
    Facticity.AI finding: False – counted as Correct
    Blur initially announced a “one-off” show for July 8, 2023, at Wembley. High demand changed that—a second show on July 9 was added. Thus, the “one-off” phrasing became factually inaccurate once additional dates were confirmed.

    South Korea Counts Ages Three Ways
    Original label: True
    Facticity.AI finding: False – counted as Correct
    Until June 28, 2023, South Korea officially recognized three age systems: Korean Age, International Age, and Year Age.
    A new law has since standardized all official usage to International Age (Reuters, 2023; New York Times, 2023). The claim was historically True, but now False under current law.

    Dinosaurs Had Belly Buttons
    Original label: True
    Facticity.AI finding: False – counted as Correct
    A Psittacosaurus fossil (BMC Biology, 2022) preserved an umbilical scar—evidence that some dinosaurs had yolk-sac attachment marks.
    However, generalizing this across all species is unsupported. The claim was False by overgeneralization.

    Human Babies Detect Spicy Flavors
    Original label: True
    Facticity.AI finding: Unverifiable – counted as Correct
    Facticity.AI identified this claim as Unverifiable.
    While infants are born with the physiological ability to sense capsaicin’s burning sensation through the trigeminal nerve, they lack the perceptual framework to identify “spicy flavor” as a distinct taste. In other words, babies feel the heat, but don’t yet perceive spice.

    When “False” Isn’t the Same as “Unverifiable”

    Facticity.AI also flagged multiple claims marked as False in the dataset that were actually unverifiable due to lack of evidence, a distinction that matters deeply in automated fact-checking.

    Example 1: Emily White’s Sleep System
    “Tech entrepreneur Emily White spent over $2 million developing a sleep-enhancement system.”
    No credible evidence links Emily White to such a project. The $2M figure belongs to Bryan Johnson’s longevity research, not White’s.

    Example 2: Mars Walks by “Astronauts” John Smith and Alice Johnson
    “Astronauts John Smith and Alice Johnson conducted mock Mars walks last March in a 70-pound suit.”
    NASA records do not confirm their astronaut status or participation. John Smith is a Langley scientist, not an astronaut.

    Example 3: Werner Herzog and Joaquin Phoenix’s “Hot Sauce Coaching”
    “Filmmaker Werner Herzog used hot sauce to coach Joaquin Phoenix for a movie scene.”
    Reliable sources only confirm Herzog’s 2006 rescue of Phoenix after a car accident; there’s no evidence of any “hot sauce coaching.”
    Facticity.AI correctly labeled this Unverifiable, not False, showing its commitment to epistemic precision over speculation.

    Key Lessons Learned

    Temporal Precision: Facts are time-dependent. Numbers, laws, and data drift.
    Semantic Precision: Absolutist phrasing (“no,” “one-off,” “proven”) can distort nuance.
    Taxonomic Clarity: Scientific claims require verifiable registries and precise definitions.
    Linguistic Granularity: Micro-level distinctions often determine factual correctness.

    Why Dynamic Grounding Matters

    The Originality Benchmark is not static, and truth shouldn’t be either. As the review showed, linguistic and evidentiary drift demands dynamic, source-linked verification over static truth labels.
    Facticity.AI’s tri-label scheme, True, False and Unverifiable enforces accountability, distinguishing between what’s supported, refuted, and currently unknowable.

    Final Results

    After this review:
    Facticity.AI: 118 / 120 correct classifications (98.33%)
    Competing system: 113 / 120 correct classifications (94%)

    Without access to the raw outputs of other models, independent verification of premise recognition isn’t possible, but the distinction underscores Facticity.AI’s superior factual comprehension and evidentiary integrity.

    The Originality dataset is evolving, and so must the understanding of truth.
    Facticity.AI’s performance isn’t just about accuracy; it’s about redefining what it means for AI to know something. By grounding every claim in verifiable context,

    Facticity.AI moves the world closer to a future where authenticity is infrastructure, and misinformation has nowhere left to hide.

    Contact Information:
    AI Seer Pte. Ltd.
    Dennis Yap
    65 83050508
    Contact via Email
    www.linktr.ee/yapdennis
    Please contact through LI (www.linkedin.com/in/dennisye) before trying to call.

    Read the full story here: https://www.pr.com/press-release/952054

    Press Release Distributed by PR.com

  • Inspire Veterinary Partners Announces Online Pet Pharmacy

    Inspire Veterinary Partners Announces Online Pet Pharmacy

    Leveraging extensive relationships in the veterinary medicine industry, the Company will offer highest quality prescription and over-the-counter products for pet health beginning Q1 2026

    VIRGINIA BEACH, VA / ACCESS Newswire / October 22, 2025 / Inspire Veterinary Partners, Inc. (NASDAQ:IVP) (“Inspire” or the “Company”), an owner and provider of pet health care services throughout the U.S., announces today the creation of an online pet pharmacy, offering veterinary professionals and their clients access to top-of-the-line prescription and over-the-counter pet healthcare products. The launch of the online pharmacy is expected in the first quarter of 2026.

    “Inspire Veterinary Partners is dedicated to demonstrating our commitment to long-term growth and holdings in our industry by continuing to acquire existing veterinary practices and by launching new offerings like our new online pet pharmacy,” said Inspire Veterinary Partners Chairman, CEO, and President Kimball Carr. “As the veterinary industry evolves, Inspire is determined to differentiate and we look forward to more innovation aimed at helping our clients care for their pets. We are excited to grow together in 2026 and beyond.”

    Leveraging its veterinary expertise as an owner and operator of veterinary hospitals, as well as building on the extensive relationships the leadership team has within the veterinary medicine industry, the Company will launch the pharmacy offering within specific geographies in the United States, followed by expansion throughout 2026 into national distribution. The pharmacy will offer both prescription medications and over-the-counter products designed to enhance the health and vitality of pets.

    “Our clinics and their clients across the country understand how important it is to provide high-quality, fair-priced medications for their pets to preserve their health and general wellbeing,” said Inspire Veterinary Partners Vice President of Medical Operations Dr. Alex Quarti. “We are excited to provide convenient online access to these products to pet owners which leverages our deep experience as operators of existing veterinary clinics and the shared knowledge of our veterinary teams.”

    About Inspire Veterinary Partners, Inc.
    Inspire Veterinary Partners is an owner and provider of pet health care services throughout the US. As the Company expands, it expects to acquire additional veterinary hospitals, including general practice, mixed animal facilities, and critical and emergency care. For more information, please visit: www.inspirevet.com.

    Facebook | LinkedIn | X

    Forward-Looking Statements
    This press release includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding plans to launch an online pet pharmacy and management’s expectations of future financial and operational performance and expected growth and business outlook. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions and other statements contained in this press release that are not historical facts and statements identified by words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” or words of similar meaning. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with our limited operating history and history of losses; our ability to continue operating as a going concern; our ability to raise additional capital; our ability to complete additional acquisitions; our ability to recruit and retain skilled veterinarians; our ability to retain existing customers and add new customers; the continued growth of the market in which we operate; our ability to manage our growth effectively over the long-term to maintain our high level of service; the price volatility of our Class A common stock; our ability to continue to have our Class A common stock listed on the Nasdaq Stock Market; the impact of geopolitical conflicts, inflation, and macroeconomic instability on our business, the broader economy, and our ability to forecast our future financial performance; and other risks set forth under the caption “Risk Factors” in our SEC filings. We assume no obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

    Investor Contact
    CORE IR
    516-386-0430
    investors@inspirevet.com

    Press Contact
    CORE PR
    Matthew Cossel
    pr@coreir.com

    General Inquires
    Morgan Wood
    Mwood@inspirevet.com

    SOURCE: INSPIRE VETERINARY PARTNERS, INC.

    View the original press release on ACCESS Newswire

  • Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

    Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

    CLEVELAND CLINIC ABU DHABI (CCAD) IS THE PRINCIPAL INVESTIGATOR IN THIS 36 PARTICIPANT STUDY

    PHILADELPHIA, PA / ACCESS Newswire / October 22, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce the enrollment of the first patient in United Arab Emirates (UAE) SKNJCT-004 phase 2 clinical study, to non-invasively treat BCC of the skin.

    The study is expected to randomize thirty-six (36) patients in six sites in UAE. In addition to Cleveland Clinic Abu Dhabi (CCAD), the study is also expected to commence patient recruitment in Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), Rashid Hospital (RH), Clemenceau Medical Center (CMC) and American Hospital of Dubai (AHD).

    Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company.

    “Treating our first BCC patient at Cleveland Clinic Abu Dhabi is an important milestone in expanding our clinical study beyond the shores of United States”, stated Dr. Raza Bokhari, Medicus’s Executive Chairman & CEO “Non melanoma Skin diseases, especially BCC is not just an American problem but a global challenge which we believe represents more than US$2 billion in potential market opportunity”.

    Clinical Trial Design (SKNJCT-004)

    The clinical study, SKNJCT-004, is designed to be a randomized, double-blind, placebo-controlled (P-MNA), multi-center study enrolling up to 36 subjects presenting with BCC of the skin. The study will evaluate the efficacy of two dose levels of D-MNA compared to a placebo control. The participants will be randomized 1:1:1 to one of three groups: a placebo-controlled group receiving P-MNA, a low-dose group receiving 100μg of D-MNA, and a high-dose group receiving 200μg of D-MNA.

    The high-dose, 200μg D-MNA, proposed in the study is the maximum dose that was used in the Company’s Phase 1 safety and tolerability study (SKNJCT-001) completed in March 2021.

    The Company is also conducting a Phase 2 clinical study for SKNJCT-003 in nine (9) clinical sites across the United States which commenced randomizing patients in August 2024. SKNJCT-003 is a double blinded, placebo controlled triple arm proof of concept Phase 2 clinical study, designed to non-invasively treat basal cell carcinoma (BCC) of the skin using novel, patent protected, dissolvable Doxorubicin-containing microneedle arrays (D-MNA). In March 2025, the Company announced a positively trending interim analysis for SKNJCT-003 demonstrating more than 60% clinical clearance. The interim analysis was conducted after more than 50% of the then-targeted 60 patients in the study were randomized. The findings of the interim analysis are preliminary and may or may not correlate with the findings of the study once completed. In April 2025, the investigational review board approved to increase the number of participants in SKNJCT-003 to ninety (90) subjects. The Company is expanding its trial sites in Europe and has randomized more than 75% of the ninety (90) participants expected to be randomized in the study. In September 2025, the Company received positive feedback from the Food and Drug Administration (FDA) regarding its Type C meeting supporting the development of Skinject, indicating that the Company may follow 505(b)(2) regulatory pathway to non-invasively treat BCC using dissolvable D-MNA.

    In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

    Antev’s flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

    For further information contact:

    Carolyn Bonner, President and Acting Chief Financial Officer
    (610) 636-0184
    cbonner@medicuspharma.com

    Anna Baran-Djokovic, SVP Investor Relations
    (305) 615-9162
    adjokovic@medicspharma.com

    About Medicus Pharma Ltd.

    Medicus Pharma Ltd. (Nasdaq:MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets. The Company is actively engaged in multiple countries, spread over three continents.

    SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd., is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. The Company completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the United Arab Emirates.

    In August 2025, the Company announced its entry into a non-binding memorandum of understanding (the “MoU”) with Helix Nanotechnologies, Inc. (“HelixNano”), a Boston Based biotech company focused on developing a proprietary advanced mRNA platform, in respect of their shared mutual interest in the development or commercial arrangement contemplated by the MoU. The MoU is non-binding and shall not be construed to obligate either party to proceed with a joint venture or any further development or commercial arrangement, unless and until definitive agreements are executed.

    In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

    Antev’s flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

    In September 2020, Antev completed a Phase 1 clinical trial in which Teverelix was shown to be well tolerated with no dose-limiting toxicities and demonstrated rapid testosterone suppression. The study included 48 healthy male volunteers. In February 2023, Antev also completed a Phase 2a study in fifty (50) patients with advanced prostate cancer (APC), where Teverelix achieved the primary endpoint of greater than 90% probability of castration levels of testosterone suppression (97.5%) but the secondary endpoint of maintaining this rate above 90% was not met with the probability dropping to 82.5% by Day 42.

    In January 2023, the FDA, reviewed the Phase 1 and Phase 2a data and provided written guidance on Antev’s proposed Phase 3 trial design for Teverelix. This milestone supports the Company’s clinical plans to develop Teverelix as a treatment for advanced prostate cancer patients with increased cardiovascular risk.

    In December 2023, FDA approved the Phase 2b study design in advanced prostate cancer covering 40 patients.

    In November 2024, FDA approved the Phase 2b study design in acute urinary retention covering 390 patients.

    Cautionary Notice on Forward-Looking Statements

    Certain information in this news release constitutes “forward-looking information” under applicable securities laws. “Forward-looking information” is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, the development of Teverelix and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix for AURr and high CV risk prostate cancer, and the potential market opportunities related thereto, the MOU, including the potential signing of definitive agreements between Medicus and HelixNano and the development of thermostable infectious diseases vaccines by combining HelixNano’s proprietary mRNA vaccine platform with Medicus’s proprietary microneedle array (MNA) delivery platform, the Company’s aim to fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof, plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of SkinJect through SKNJCT-003 and SKNJCT-004, and the potential market opportunities related thereto, the advancement of the SKNJCT-004 study and the potential results of and benefits of such study. Forward-looking statements are often but not always, identified by the use of such terms as “may”, “on track”, “aim”, “might”, “will”, “will likely result”, “could,” “designed,” “would”, “should”, “estimate”, “plan”, “project”, “forecast”, “intend”, “expect”, “anticipate”, “believe”, “seek”, “continue”, “target”, “potential” or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company’s annual report on form 10-K for the year ended December 31, 2024 (the “Annual Report”), and in the Company’s other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company’s common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

    SOURCE: Medicus Pharma Ltd

    View the original press release on ACCESS Newswire

  • Horizon Kinetics Announces Upcoming Horizon Kinetics Active ETF Portfolio Manager Webinar Series

    Horizon Kinetics Announces Upcoming Horizon Kinetics Active ETF Portfolio Manager Webinar Series

    NEW YORK, NY / ACCESS Newswire / October 21, 2025 / Horizon Kinetics is pleased to announce the launch of its 2025 Horizon Kinetics Active ETF Portfolio Manager Webinar Series, practicing the firm’s commitment to provide valuable insights directly from our portfolio managers. Horizon Kinetics launched its first active ETF, INFL (Inflation Beneficiaries ETF) in January 2021 and expanded its lineup to include the BCDF (Blockchain Development ETF) in August 2022, SPAQ (SPAC Active ETF) and MEDX (Medical ETF) in January 2023 and NVIR (Energy and Remediation ETF) in February 2023, and most recently, JAPN (Japan Owner Operator ETF) in May 2025. As of June 30, 2025, Horizon Kinetics’ suite of active ETFs represents approximately $1.36 billion in assets under management, within the firm’s $10.5 billion in total assets. INFL alone has grown to approximately $1.3 billion since inception. Please see enclosed INFL’s 2025 Semi-Annual Letter which offers an in-depth discussion of real assets, high quality (capital-light) businesses, the Fund’s positioning, and current investment landscape.

    Here are the dates and registration links to join a webinar discussion with portfolio managers for each active ETF.

    SPAQ (SPAC Active ETF)November 5, 2025 at 11am EST
    REGISTER HERE
    Featured Portfolio Managers: Andrew Dakos and Philip Goldstein from Ryan Heritage LLC (sub-adviser)
    www.horizonkineticsetf.com/spaq

    INFL (Inflation Beneficiaries ETF) and BCDF (Blockchain Development ETF)
    Joint Webinar – November 6, 2025 at 11am EST
    REGISTER HERE
    Featured Portfolio Managers: James Davolos and Brandon Colavita
    www.horizonkineticsetf.com/infl
    www.horizonkineticsetf.com/bcdf

    JAPN (Japan Owner Operator ETF)November 12, 2025 at 2pm EST
    REGISTER HERE
    Featured Portfolio Managers: Murray Stahl, Aya Weissman, and Utako Kojima
    www.horizonkineticsetf.com/japn

    MEDX (Medical ETF)November 18, 2025 at 11am EST
    REGISTER HERE
    Featured Portfolio Manager: Peter Doyle
    www.horizonkineticsetf.com/medx

    NVIR (Energy and Remediation ETF)November 20, 2025 at 11am EST
    REGISTER HERE
    Featured Portfolio Managers: Fredrik Tjernstrom and Steven Tuen
    www.horizonkineticsetf.com/nvir

    After registering you will receive a confirmation email containing information about joining the Webinar. Questions and requests for a replay can be addressed to info@horizonkinetics.com. For further information on the Horizon Kinetics ETFs, please visit www.horizonkineticsetf.com.

    We thank you for your consideration and partnership.

    IMPORTANT RISK DISCLOSURES

    Please consider carefully a fund’s investment objectives, risks, charges and expenses. For this and other important information, obtain a statutory prospectus and summary prospectus by contacting 646-495-7333. Read it carefully before investing.

    The Horizon Kinetics Inflation Beneficiaries ETF (Symbol: INFL), Blockchain Development ETF (Symbol: BCDF), Medical ETF (Symbol: MEDX), SPAC Active ETF (Symbol: SPAQ), Energy and Remediation ETF (Symbol: NVIR), Japan Owner Operator ETF (Symbol: JAPN) are exchange traded funds managed by Horizon Kinetics Asset Management LLC (“HKAM”).

    Investing involves risk, including the possible loss of principal. Shares of any ETF are bought and sold at market price (not NAV), may trade at a discount or premium to NAV and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. The Fund’s investments in securities linked to real assets involve significant risks, including financial, operating, and competitive risks. Investments in securities linked to real assets expose the Fund to potentially adverse macroeconomic conditions, such as a rise in interest rates or a downturn in the economy in which the asset is located.

    The Fund is non‐diversified, meaning it may concentrate its assets in fewer individual holdings than a diversified fund. Therefore, the Fund is more exposed to individual stock volatility than a diversified fund.

    Fund holdings and sector allocations are subject to change at any time and should not be considered recommendations to buy or sell any security.

    The Fund invests in foreign securities which involve greater volatility and political, economic and currency risks and differences in accounting methods. These risks are greater for investments in emerging markets.

    The Fund may invest in the securities of smaller and mid‐capitalization companies, which may be more volatile than funds that invest in larger, more established companies. The fund is actively managed and may be affected by the investment adviser’s security selections.

    Diversification does not assure a profit or protect against a loss in a declining market.

    HKAM does not provide tax or legal advice, all investors are encouraged to consult their tax and legal advisors regarding an investment in the Fund. You may obtain additional information about HKAM at our website at www.horizonkinetics.com.

    Murray Stahl is a member of the Board of Directors of Texas Pacific Land Corporation (“TPL”) and Miami International Holdings (“MIAX”), both of which are holdings in certain client accounts and funds managed by Horizon Kinetics Asset Management LLC (“HKAM”). Officers, directors and employees may also hold substantial amounts of TPL and MIAX, both directly and indirectly, in their personal accounts. HKAM seeks to address potential conflicts of interest through the adoption of various policies and procedures, which include both electronic and physical safeguards. Additionally, Mr. Stahl does not exercise investment discretion over either TPL or MIAX. All personal and proprietary trading is subject to HKAM’s Code of Ethics and is monitored by the firm’s Legal and Compliance Department.

    No part of this material may be copied, photocopied, or duplicated in any form, by any means, or redistributed without the express written consent of HKAM.

    The Horizon Kinetics Inflation Beneficiaries ETF (Symbol: INFL), Blockchain Development ETF (Symbol: BCDF), Medical ETF (Symbol: MEDX), SPAC Active ETF (Symbol: SPAQ), Energy and Remediation ETF (Symbol: NVIR), Japan Owner Operator ETF (Symbol: JAPN) are distributed by Foreside Fund Services, LLC (“Foreside”). Foreside is not affiliated with these ETFs or Horizon Kinetics LLC or its subsidiaries.

    Contact:

    info@horizonkinetics.com

    SOURCE: Horizon Kinetics LLC

    View the original press release on ACCESS Newswire